Pergolide monotherapy in the treatment of early PD : A randomized, controlled study

摘要: Objective: To determine whether pergolide monotherapy provides symptomatic relief in early PD. Background: Early treatment with dopamine agonists may reduce the risk of motor fluctuations, which are most likely linked to levodopa therapy. Pergolide, a D1-D2 agonist, has been studied as “add on” therapy PD, but no controlled clinical trial studying efficacy is available. Methods: The and tolerability were evaluated multicenter, double-blind, randomized, parallel-group, 3-month versus placebo. Patients diagnosis idiopathic modified Hoehn & Yahr score 1 3, greater than 14 points on Unified Parkinson’s Disease Rating Scale (UPDRS) part III at baseline enrolled study (pergolide, n = 53; placebo, 52). Results: Patient characteristics entry comparable two groups. group showed significantly percent responders (defined ≥30% decrease UPDRS end point) compared placebo (57% 17%; p Conclusion: This suggests that be an efficacious well-tolerated first-line patients early-stage